Medicare Price ‘Negotiation’ Process Gets Broad Brush Treatment In New Law
Executive Summary
With enactment of the drug pricing reform provisions in the Inflation Reduction Act, stakeholders now turn their attention to the implementing regulations that will be developed by the Centers for Medicare and Medicaid Services.
You may also be interested in...
Medicare Price ‘Negotiation’ Process Could Enable National Value Framework – CMS’ Blum
Centers for Medicare and Medicaid Services chief operating officer Jonathan Blum discusses implementation of an unprecedented new price setting program and how it might impact value-based pricing more broadly in a recent interview with Health Affairs.
MedPAC’s Message To Congress: Drug Pricing Still Needs Attention
The US Medicare Payment Advisory Commission is continuing its work on proposals to overhaul federal payment for physician administered drugs. That is an ominous message for the biopharma industry as it reels from passage of dramatic pricing legislation earlier this year.
Medicare Part B And Accelerated Approvals: MedPAC Mulls Use Of CED Versus Payment Caps
Medicare advisory panel discusses ongoing issues around launch prices that were not addressed by the government price controls targeting older drugs enacted as part of the Inflation Reduction Act.